NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis $5.58 +0.29 (+5.44%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Corvus Pharmaceuticals Stock (NASDAQ:CRVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Corvus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$5.22▼$5.6450-Day Range$3.73▼$5.4352-Week Range$2.54▼$10.00Volume468,075 shsAverage Volume800,468 shsMarket Capitalization$415.64 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company Overview Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California. Read More Corvus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCRVS MarketRank™: Corvus Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 449th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorvus Pharmaceuticals has received no research coverage in the past 90 days.Read more about Corvus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 5.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.50% of the float of Corvus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently decreased by 2.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.50% of the float of Corvus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently decreased by 2.12%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment0.14 News SentimentCorvus Pharmaceuticals has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Corvus Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,893,541.00 in company stock.Percentage Held by Insiders28.50% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corvus Pharmaceuticals' insider trading history. Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Stock News HeadlinesHC Wainwright Analysts Raise Earnings Estimates for CRVSAugust 16, 2025 | americanbankingnews.comResearch Analysts Set Expectations for CRVS FY2028 EarningsAugust 14, 2025 | americanbankingnews.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 22 at 2:00 AM | InvestorPlace (Ad)Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 CatalystsAugust 12, 2025 | seekingalpha.comCorvus Pharmaceuticals (NASDAQ:CRVS) Upgraded to Hold at Wall Street ZenAugust 11, 2025 | americanbankingnews.comCorvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comCorvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) top owners are retail investors with 48% stake, while 33% is held by institutionsAugust 5, 2025 | finance.yahoo.comSee More Headlines CRVS Stock Analysis - Frequently Asked Questions How have CRVS shares performed this year? Corvus Pharmaceuticals' stock was trading at $5.35 on January 1st, 2025. Since then, CRVS stock has increased by 4.3% and is now trading at $5.5780. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its earnings results on Thursday, August, 7th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.03. Read the conference call transcript. When did Corvus Pharmaceuticals IPO? Corvus Pharmaceuticals (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' top institutional shareholders include Orbimed Advisors LLC (9.62%), Foresite Capital Management VI LLC (2.32%), Perceptive Advisors LLC (1.93%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include Peter A Thompson, Richard A Md Miller, William Benton Jones, Leiv Lea and Linda Grais. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Rockwell Medical (RMTI), Axcelis Technologies (ACLS) and Protagonist Therapeutics (PTGX). Company Calendar Last Earnings8/07/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVS CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Corvus Pharmaceuticals$15.00 High Price Target$21.00 Low Price Target$11.00 Potential Upside/Downside+168.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-28.61% Return on Assets-18.05% Debt Debt-to-Equity RatioN/A Current Ratio8.91 Quick Ratio8.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book5.16Miscellaneous Outstanding Shares74,514,000Free Float53,278,000Market Cap$415.64 million OptionableOptionable Beta0.42 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:CRVS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.